Sun Pharma Canada, a subsidiary of Sun Pharmaceutical Industries, has secured Health Canada’s approval for their pioneering acne treatment, WINLEVI (clascoterone cream 1%). This marks the first approval of an androgen receptor inhibitor for topical treatment of acne vulgaris in patients aged 12 and older, presenting a groundbreaking advancement in acne treatments for Canadian patients […]
Kintor Pharmaceutical said that it has wrapped up patient enrollment for the phase 2 clinical trial of KX-826 (pyrilutamide) in China for the treatment of acne vulgaris. The Chinese biotech company has enrolled a total of 160 patients for the mid-stage clinical trial. According to Kintor Pharmaceutical, the randomized, double-blind, placebo-controlled clinical study to be […]
AMZEEQ FDA approval : Israeli specialty pharma company Foamix Pharmaceuticals has bagged approval from the US Food and Drug Administration (FDA) for AMZEEQ (minocycline) topical foam, 4% for the treatment of moderate to severe acne. Previously known as FMX101, AMZEEQ has been indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne […]
Ortho Dermatologics, a division of Bausch Health Companies, has achieved a significant milestone with the FDA approval of Altreno lotion (tretinoin 0.05%) for the treatment of acne vulgaris in patients aged 9 years and older. This approval marks Altreno as the first tretinoin formulation available in a lotion format, designed to enhance patient experience with […]